Peptide Therapeutics Market Overview:
The global peptide therapeutics market size reached USD 42.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach USD 86.9 Billion by 2032, exhibiting a growth rate (CAGR) of 7.9% during 2024-2032. The increasing prevalence of chronic diseases, advancements in peptide synthesis technologies, the rising demand for targeted therapies and biologics, the growing effectiveness of peptides in treating various conditions, including cancer and metabolic disorders, and enhanced regulatory support are some of the major factors propelling the market demand for peptide therapeutics.
Report Attribute
|
Key Statistics
|
Base Year
|
2023
|
Forecast Years
|
2024-2032
|
Historical Years
|
2018-2023
|
Market Size in 2023
|
USD 42.8 Billion |
Market Forecast in 2032
|
USD 86.9 Billion |
Market Growth Rate 2024-2032 |
7.9% |
Peptides are efficacious and selective signaling molecules that bind to specific cell surface receptors, such as ion channels and G protein-coupled receptors (GPCRs) and trigger intracellular effects. They are employed in the pharmaceutical industry to design novel regenerative therapeutics that can target a wide range of cells and manipulate their responses. These therapeutics are less toxic, relatively safe, and well-tolerated than other treatment options. As a result, they are gaining traction in clinical practices worldwide to manage cancer, injuries, infectious diseases, metabolic disorders, and aesthetic concerns.
Peptide Therapeutics Market Trends:
Increasing Prevalence of Chronic Diseases
The increasing prevalence of chronic diseases, such as cancer, diabetes, and cardiovascular conditions, is a primary factor propelling the peptide therapeutics market growth. Peptides, known for their high specificity and ability to target precise biological processes, offer promising treatment options for chronic diseases, which often require long-term and effective management solutions. In line with this, with a rise in lifestyle-related health conditions and an aging global population, the demand for innovative, targeted therapies has surged. Peptide therapeutics align well with this need due to their unique mechanisms of action, which minimize side effects as compared to traditional small-molecule drugs. Moreover, government and pharmaceutical sector investments in research and development (R&D) drive the creation of novel peptides, expanding treatment possibilities. In addition to this, advancements in peptide synthesis, formulation, and delivery have enhanced their bioavailability and stability, which is expected to increase the overall peptide therapeutics market share. Consequently, the peptide therapeutics market continues to experience robust growth, addressing critical unmet needs in chronic disease management.
Advancements in Peptide Synthesis and Delivery Technologies
Advancements in peptide synthesis and drug delivery technologies are significantly enhancing the development and efficacy of peptide therapeutics which is contributing to the market growth across the globe. Innovative techniques, such as solid-phase peptide synthesis (SPPS) and automated synthesis platforms, have streamlined the production of high-quality peptides, making them more efficient and cost-effective. Moreover, improved delivery systems, such as nanoparticle formulations and transdermal patches, have addressed challenges related to peptide stability and bioavailability which is expected to create a positive peptide therapeutics market outlook. In addition to this, these technological innovations not only enhance the therapeutic potential of peptides but also expand their applications across various medical fields, including oncology, endocrinology, and immunology. As these advancements continue to evolve, they are expected to propel the peptide therapeutics market by facilitating the development of new and effective peptide-based treatments.
Growing Focus on Personalized Medicine
The increasing emphasis on personalized medicine is acting as another major growth-inducing factor in the peptide therapeutics market across the globe. According to the peptide therapeutics market analysis, since personalized medicine aims to tailor treatments to individual patients based on their genetic, environmental, and lifestyle factors, this is boosting the market demand. Peptides are particularly well-suited for this approach, as they can be designed to target specific pathways and biological markers unique to individual patients. The rise of genomics and biomarker research is facilitating the identification of patient populations that may benefit from peptide-based therapies. As healthcare systems increasingly recognize the value of personalized treatments in improving patient outcomes and minimizing side effects, the demand for peptide therapeutics is expected to rise. This shift toward personalized medicine is shaping the future landscape of the pharmaceutical industry.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global peptide therapeutics market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type, type of manufacturer, synthesis technology, routes of administration, and application.
Breakup by Type:
Breakup by Type of Manufacturer:
Breakup by Synthesis Technology:
- Solid Phase Peptide Synthesis
- Liquid Phase Peptide Synthesis
- Hybrid Technology
Breakup by Routes of Administration:
Breakup by Application:
- Gastrointestinal Disorders
- Neurological Disorders
- Metabolic Disorders
- Cancer
- Others
Breakup by Region:
- North America
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Middle East and Africa
Competitive Landscape:
The report has also provided a comprehensive analysis of the competitive landscape in the global peptide therapeutics market. Detailed profiles of all major companies have also been provided. Some of the companies covered include:
- Amgen Inc.
- Apitope International NV
- Arch Biopartners Inc.
- AstraZeneca plc
- Circle Pharma Inc.
- Corden Pharma GmbH
- F. Hoffmann-La Roche AG
- Ipsen Group
- Lonza Group AG
- Novo Nordisk A/S
- Pfizer Inc.
- Teva Pharmaceuticals Industries Ltd.
- Zealand Pharma A/S
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Peptide Therapeutics Market News:
- In January 2024, WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech, and medical device industries to advance discoveries and deliver groundbreaking treatments to patients, announced the commissioning of its two new peptide manufacturing plants, one at its Changzhou facility and another at the new Taixing site in China. This significant expansion has increased the company’s Solid-Phase Peptide Synthesis (SPPS) total reactor volume to 32,000 liters, addressing the surging global demand for peptide therapeutics.
- In March 2023, Ono Pharmaceutical Co., Ltd. announced that it has entered into a drug discovery collaboration agreement with PeptiDream Inc., to discover and develop novel macrocyclic constrained peptide drugs against multiple targets of Ono’s interest.
- In May 2024, Novartis and PeptiDream expanded their peptide discovery collaboration with a new agreement worth over $2.8bn. The multi-program agreement will see PeptiDream use its proprietary Peptide Discovery Platform System technology to identify and optimize macrocyclic peptides against targets chosen by Novartis.
Peptide Therapeutics Market Report Scope:
Report Features |
Details |
Base Year of the Analysis |
2023 |
Historical Period |
2018-2023 |
Forecast Period |
2024-2032 |
Units |
Billion USD |
Segment Coverage |
Type, Type of Manufacturer, Synthesis Technology, Routes of Administration, Application, Region |
Region Covered |
Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered |
United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered |
Amgen Inc., Apitope International NV, Arch Biopartners Inc., AstraZeneca plc, Circle Pharma Inc., Corden Pharma GmbH, F. Hoffmann-La Roche AG, Ipsen Group, Lonza Group AG, Novo Nordisk A/S, Pfizer Inc., Teva Pharmaceuticals Industries Ltd. and Zealand Pharma A/S |
Customization Scope |
10% Free Customization |
Post-Sale Analyst Support |
10-12 Weeks |
Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |